Edition:
United States

GenMark Diagnostics Inc (GNMK.OQ)

GNMK.OQ on NASDAQ Stock Exchange Global Market

9.42USD
12:09pm EDT
Change (% chg)

$-0.10 (-1.05%)
Prev Close
$9.52
Open
$9.47
Day's High
$9.47
Day's Low
$9.30
Volume
18,342
Avg. Vol
128,085
52-wk High
$13.67
52-wk Low
$8.89

Latest Key Developments (Source: Significant Developments)

Genmark Diagnostics Q2 earnings per share view $0.32
Tuesday, 1 Aug 2017 08:05am EDT 

Aug 1 (Reuters) - Genmark Diagnostics Inc :Genmark reports second quarter 2017 results.Q2 loss per share $0.37.Q2 revenue $12.4 million versus I/B/E/S view $12.4 million.Q2 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.Genmark Diagnostics Inc - ‍company ended quarter with $106.5 million in cash and cash equivalents​.  Full Article

GenMark diagnostics commences public offering of common stock
Monday, 12 Jun 2017 04:01pm EDT 

June 12 (Reuters) - Genmark Diagnostics Inc ::Genmark Diagnostics commences public offering of common stock.Genmark Diagnostics Inc - commenced an underwritten public offering of $65 million of shares of its common stock.J.P. Morgan and BofA Merrill lynch are acting as joint book-running managers for offering.Intends to grant underwriters a 30-day option to purchase up to $9.75 million of additional shares.  Full Article

Genmark receives FDA 510(k) market clearance for its Eplex instrument and respiratory pathogen panel
Monday, 12 Jun 2017 08:05am EDT 

June 12 (Reuters) - Genmark Diagnostics Inc :Genmark receives FDA 510(k) market clearance for its eplex® instrument and respiratory pathogen panel.Says expects q2 2017 revenues in range of $12 to $13 million.Says for full year 2017, co continues to expect revenue in range of $65 to $70 million.Genmark diagnostics says it intends to draw down an additional $15 million under terms of its existing debt facility.Genmark diagnostics - revenue from eplex installations at u.s. Customer sites expected to positively impact second half of 2017.Fy2017 revenue view $67.3 million -- Thomson Reuters I/B/E/S.Q2 revenue view $13.8 million -- Thomson Reuters I/B/E/S.  Full Article

Genmark Diagnostics reports Q1 revenue $12.5 million
Tuesday, 2 May 2017 04:05pm EDT 

May 2 (Reuters) - Genmark Diagnostics Inc :Genmark Diagnostics reports first quarter 2017 results.Q1 revenue $12.5 million versus I/B/E/S view $12.5 million.Q1 loss per share $0.30.Sees FY 2017 revenue $65 million to $70 million.Q1 earnings per share view $-0.28 -- Thomson Reuters I/B/E/S.Genmark Diagnostics Inc - For full year 2017, company continues to expect revenue in range of $65 to $70 million and gross margin in range of 48-52%..  Full Article

Genmark Diagnostics Q1 preliminary revenue $12.5 mln
Thursday, 20 Apr 2017 06:58pm EDT 

April 20 (Reuters) - Genmark Diagnostics Inc :Genmark achieves ce mark for its eplex® blood culture identification fungal pathogen panel.reports positive preliminary q1 revenues of $12.5 million up 13% versus prior year.during q1, it added more than 15 customer agreements.Q1 revenue view $12.5 million -- Thomson Reuters I/B/E/S.  Full Article

Genmark Diagnostics Q4 loss per share $0.27
Tuesday, 28 Feb 2017 04:05pm EST 

Genmark Diagnostics Inc : Genmark diagnostics reports fourth quarter and full year 2016 results . Q4 loss per share $0.27 . Fy2017 revenue view $67.5 million -- Thomson Reuters I/B/E/S . Q4 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S .Sees fy 2017 revenue $65 million to $70 million.  Full Article

Genmark announces preliminary Q4 2016 financial results
Tuesday, 10 Jan 2017 08:05am EST 

Genmark Diagnostics Inc : Genmark announces preliminary Q4 2016 financial results . Sees FY 2016 revenue $49.2 million .Q4 revenue $14.9 million versus I/B/E/S view $14.8 million.  Full Article

GenMark Diagnostics submits 510(k) applications to the FDA
Thursday, 22 Dec 2016 08:05am EST 

Genmark Diagnostics Inc : Genmark Diagnostics Inc - expect blood culture id family of panels to be available in Europe during q1 of 2017 .Genmark Diagnostics submits 510(k) applications to the FDA for eplex® sample-to-answer instrument and respiratory pathogen panel.  Full Article

Morgan Stanley reports 5 pct passive stake in GenMark Diagnostics as of Aug 17
Monday, 29 Aug 2016 05:21pm EDT 

GenMark Diagnostics Inc :Morgan Stanley reports 5.0 percent passive stake in GenMark Diagnostics Inc as of August 17 -Sec filing.  Full Article

GenMark Diagnostics reports Q2 loss per share of $0.30
Thursday, 28 Jul 2016 04:05pm EDT 

GenMark Diagnostics Inc : For full year 2016, company continues to expect gross margin expectations have increased to 57% to 59% . Fy2016 earnings per share view $-1.23 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.30 . Sees fy 2016 revenue $47 million to $51 million . Q2 revenue rose 64 percent to $12.5 million . Q2 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S .Q2 revenue view $9.6 million -- Thomson Reuters I/B/E/S.  Full Article